Results 161 to 170 of about 1,191,463 (297)
Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective
Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.Marika Pane, Giorgia Coratti, Chiara Cutrì, Antonio Varone, Riccardo Masson, Adele D'Amico, Valeria Sansone, Sonia Messina, Federica Ricci, Chiara Ticci, Claudio Bruno, Caterina Agosto, Francesca Benedetti, Antonella Pini, Sabrina Siliquini, Massimiliano Filosto, Alberto Zambon, Ilaria Bitetti, Maria Rosaria Manna, Claudia Dosi, Riccardo Zanin, Stefano Parravicini, Roberto De Sanctis, Giulia Stanca, Michela Catteruccia, Michele Tosi, Irene Mizzoni, Emilio Albamonte, Valentina Franchino, Maria Sframeli, Ilaria Cavallina, Elena Procopio, Michele Sacchini, Simone Morando, Noemi Brolatti, Federica Trucco, Gaia Scarpini, Elena Briganti, Beatrice Berti, Concetta Palermo, Daniela Leone, Stefano C. Previtali, Eugenio Mercuri, the ITASMAC working group +43 morewiley +1 more sourceModeling risk factors and confounding effects in stroke [PDF]
, 2010 A Denes, A Ergul, A Martin, A Paganini-Hill, A Sauter, A Tajima, A Tedgui, A Vogelgesang, AE Malavazos, AM Dorrance, AM Romanic, AS Plump, AY Poppe, B Boden-Albala, B Mathew, BC Wexler, BJ Marsh, BM Kelly, BQ Zhao, BW McColl, BW McColl, C Alba, C Gallou-Kabani, C Meisel, C Warlow, C Weber, C Woiciechowsky, CD Lynch, CM Lawes, DA Rees, DJ Gladstone, DO Nelson, DT Laskowitz, E Farkas, E Morikawa, E Sena, E Stabile, EI Mangiarua, EL Phelan, F Amiri, F Lago, F Liu, FC Barone, G Bianchi, G Hu, G Pergola De, G Pergola De, G Stoll, GH Lee, GJ Hankey, GJ Zoppo Del, GL Baumbach, GM Courten-Myers de, GR Meneely, GS Getz, GW Payne, GZ Feuerstein, H Boutin, H Chen, H Imai, H Kamada, H Nawashiro, H Offner, H Takaba, H Yamakawa, H Yao, HB Hubert, HC Emsley, HC Emsley, HC Emsley, I Pineau, IL Katzan, J Boltze, J Herz, J Jawien, J Mayer, J Ogata, J Panes, J Speakman, J Wagner, J Yrjanheikki, J Zeng, JA Gratton, JC Copin, JC Russell, JL Goldstein, JM Lee, JM Osmond, JP Bastard, JP Ingraham, JP Rapp, K Fredriksson, K Horsburgh, K Kariko, K Mayanagi, K Okamoto, K Prass, K Sundquist, K Takaya, KA Darvall, KM Cullen, KM Rexrode, KT Khaw, L Bomont, L Herberg, L Liu, L Smeeth, LM Delbridge, LM Zucker, LS Williams, M Fisher, M Fujishima, M Fukushima, M Grossetete, M Jacewicz, M Kittaka, M Lu, M Richardson, M Shibota, M Vincent, M Yong, MD Ginsberg, MG Hamilton, MJ Alberts, MK Baskaya, MM Kaarisalo, MR Bigio Del, MR Macleod, MR Macleod, MS Winzell, N Nagai, NA Crossley, NC Huang, NJ Alkayed, NJ Spratt, O Gualillo, O Takeuchi, P Bendel, P Coyle, P Coyle, P Coyle, P Meden, P Villa, PC Churchill, PC Tang, PD Hurn, PM Hughes, PW Wilson, R Bright, R Hilker, R Prado, RE Myers, RL Sacco, RS Surwit, RW Mahley, RY Wang, S Brint, S Kawamura, S Lehnardt, S Murphy, S Prusty, S Roussel, S Sriskandan, S Terao, SA Kraft, SC Palmon, SC Woods, SG Soriano, SH Suk, SH Zhang, SJ Vannucci, SR Ennis, SS Kang, ST Yang, STAIR, T Els, T Jeerakathil, T Kurth, T Moreira, T Nabika, T Sukamoto, TK Toung, TV Arumugam, U Dirnagl, U Kilic, V Darsalia, VA DiNapoli, Y Liu, Y Matsuo, Y Nakashima, Y Winter, Y Yamori, Y Zhang, YD Cheng +193 morecore +1 more sourceReperfusion‐Dependent Outcomes After Endovascular Thrombectomy Stratified by NIHSS‐ASPECTS Clinical‐Core Mismatch
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective
This analysis evaluates the effect of successful reperfusion on functional outcomes after MT, stratified by admission National Institutes of Health Stroke Scale (NIHSS) and Alberta Stroke Program Early CT Score (ASPECTS) as surrogates for clinical‐core mismatch, using multicenter registry data.Felix Schlicht, Lukas Meyer, Gabriel Broocks, Matthias Bechstein, Christian Thaler, Christian Heitkamp, Laurens Winkelmeier, Vincent Geest, Alexander Heitkamp, Maximilian Jungnitz, Gregor Peter, Luca Meucci, Tobias Faizy, Jawed Nawabi, Caspar Brekenfeld, Fabian Flottmann, Maximilian Schell, Alexandros Hadjilaou, Uta Hanning, Götz Thomalla, Jens Fiehler, Susanne Gellißen, Helge C. Kniep, for the German Stroke Registry Endovascular Treatment, (GSR‐ET) Alexander Nave, Anna Alegiani, Annerose Mengel, Arno Reich, Bernd Eckert, Charlotte Pietrock, Christian Nolte, Eberhard Siebert, Fabian Flottmann, Fee Keil, Franziska Dorn, Gabor Petzold, Götz Thomalla, Hanna Zimmermann, Jan Borggrefe, Jan Hendrik Schäfer, Jens Fiehler, Joachim Röther, Klaus Gröschel, Lars Kellert, Mario Abruscato, Maximilian Schell, Omid Nikoubashman, Peter Schellinger, Silke Wunderlich, Steffen Tiedt, Sven Thonke, Timo Uphaus, Tobias Boeckh‐Behrens, Ulrike Ernemann +53 morewiley +1 more sourceCracking the Code: Genotype–Phenotype Correlation Models in Sarcoglycanopathies
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective
Sarcoglycanopathies are among the most severe limb‐girdle muscular dystrophies (LGMD), though milder presentations have been described. These diseases are primarily caused by missense variants, but the limited predictability of their effect on protein maturation, complex formation, and transport has hindered reliable genotype ...Leonela Luce, Goknur Selen Kocak, José Verdú‐Díaz, Jorge Alonso‐Pérez, Kristl G. Claeys, Tanya Stojkovic, Gorka Fernández‐Eulate, Pascal Laforêt, Najoua Miladi, Filipe Di Pace, Cristiane Araujo Martins Moreno, Edmar Zanoteli, Conrad C. Weihl, Volker Straub, Ana Töpf, Jordi Díaz‐Manera, Sarcoglycan European Cohort Consortium, Adele D′Amico, Adolfo López de Munain, Alicia Alonso‐Jiménez, Ana Camacho‐Salas, Andrea Gangfuß, Andrés Nascimento, Anna Sarkozy, Anneke J. van der Kooi, Arturo Fraga‐Bau, Béla Melegh, Benedikt Schoser, Bjarne Udd, Blaz Koritnik, Carlos Ortez, Chiara Marini Bettolo, Chiara Panicucci, Claudia Weiss, Claudio Bruno, Claudio Semplicini, Cristina Dominguez‐González, Cristina Garrido, David Gómez‐Andrés, Edoardo Malfatti, Elena Pegoraro, Elke De Vos, Francina Munell, Gabriele Dekomien, Giacomo Pietro Comi, Giorgio Tasca, Isabelle Richard, Jan L. De Bleecker, Jana Haberlová, Jesper Helbo Storgaard, Johanna Palmio, John Vissing, Juan Carlos de Leon‐Hernández, Kinga Hadzsiev, Laura Costa‐Comellas, Lea Leonardis, Leroy ten Dam, Lidia González‐Quereda, Luca Bello, Luisa Politano, Manuela Santos, Marianne de Visser, Marie Rohlenová, Matteo Garibaldi, Michela Guglieri, Nicolas Deconinck, Nicoline Løkken, Omar Abdel‐Mannan, Pia Gallano, Roberto Fernández‐Torrón, Ulrike Schara‐Schmidt, Vincenzo Nigro, Vittoria Zangaro +72 morewiley +1 more sourceReply to Mitsuboshi, "Enhancing result reliability by addressing potential confounding factors". [PDF]
Microbiol SpectrIshigo T, Matsumoto K, Yoshida H, Tanaka H, Ibe Y, Fujii S, Fukudo M, Fujihara H, Yamaguchi F, Ebihara F, Maruyama T, Hamada Y, Samura M, Nagumo F, Komatsu T, Tomizawa A, Takuma A, Chiba H, Nishi Y, Enoki Y, Taguchi K, Suzuki A. +21 moreeuropepmc +1 more sourceMultiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants
Annals of Clinical and Translational Neurology, EarlyView.Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective
Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree +12 morewiley +1 more source
